EUVIMEDEUVIMED entdecken
Crossref

Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group

Christian Pfrepper, Robert Klamroth, Johannes Oldenburg, Katharina Holstein, Hermann Eichler, Christina Hart, Patrick Moehnle, Kristina Schilling, Karolin Trautmann-Grill, Mohammed Alrifai, Cihan Ay, Wolfgang Miesbach und 2 weitere

Hämostaseologie · 01.12.2024 · 44 (06) · 466-471

DOI: 10.1055/a-2197-9738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 01.12.2024. Verfasst von Christian Pfrepper und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital Leipzig, Leipzig, German…. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Standard treatment consists of bleeding control with bypassing agents and immunosuppressive therapy. Emicizumab is a bispecific antibody that mimics the function of activated FVIII irrespective of the presence of neutralizing antibodies. Recently, the GTH-AHA-EMI study demonstrated that emicizumab prevents bleeds and allows to postpone immunosuppression, which may influence future treatment strategies.

Aim

To provide clinical practice recommendations on the use of emicizumab in AHA.

Methods

A Delphi procedure was conducted among 33 experts from 16 German and Austrian hemophilia care centers. Statements were scored on a scale of 1 to 9, and agreement was defined as a score of ≥7. Consensus was defined as ≥75% agreement among participants, and strong consensus as ≥95% agreement.

Results

Strong consensus was reached that emicizumab is effective for bleed prophylaxis and should be considered from the time of diagnosis (100% consensus). A fast-loading regimen of 6 mg/kg on day 1 and 3 mg/kg on day 2 should be used if rapid bleeding prophylaxis is required (94%). Maintenance doses of 1.5 mg/kg once weekly should be given (91%). Immunosuppression should be offered to patients on emicizumab if they are eligible based on physical status (97%). Emicizumab should be discontinued when remission of AHA is achieved (97%).

Conclusion

These GTH consensus recommendations provide guidance to physicians on the use of emicizumab in AHA and follow the results of clinical trials that have shown emicizumab is effective in preventing bleeding in AHA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificAntibodies, Monoclonal, HumanizedHumansFactor VIIIPractice Guidelines as TopicHemorrhage

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIII

Autor:innen und Institutionen

  • Division of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital Leipzig, Leipzig, Germany.
  • Department of Internal Medicine, Vascular Medicine and Coagulation Disorders, Vivantes Clinic Friedrichshain, Berlin, Germany.
  • Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
  • Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Clinical Hemostaseology and Transfusion Medicine, Saarland University Hospital, Homburg/Saar, Germany.
  • Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.

Zitieren

APA

Pfrepper, C., Klamroth, R., Oldenburg, J., Holstein, K., Eichler, H., Hart, C., Moehnle, P., Schilling, K., Trautmann-Grill, K., Alrifai, M., Ay, C., Miesbach, W., Knoebl, P., & Tiede, A. (2024). Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group. Hämostaseologie, 44(06), 466-471. https://doi.org/10.1055/a-2197-9738

Vancouver

Pfrepper C, Klamroth R, Oldenburg J, Holstein K, Eichler H, Hart C, et al. Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group. Hämostaseologie. 2024;44(06):466-471. doi:10.1055/a-2197-9738

BibTeX
@article{Pfrepper2024,
  author = {Pfrepper, Christian and Klamroth, Robert and Oldenburg, Johannes and Holstein, Katharina and Eichler, Hermann and Hart, Christina and Moehnle, Patrick and Schilling, Kristina and Trautmann-Grill, Karolin and Alrifai, Mohammed and Ay, Cihan and Miesbach, Wolfgang and Knoebl, Paul and Tiede, Andreas},
  title = {Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group},
  journal = {Hämostaseologie},
  year = {2024},
  volume = {44},
  number = {06},
  pages = {466--471},
  doi = {10.1055/a-2197-9738}
}
Kostenlos starten →